Agilent and UC San Diego Launch Center of Excellence in Cellular Intelligence
2024年4月2日 - 9:00PM
ビジネスワイヤ(英語)
Agilent CoE supports research on how cells function and adapt,
revealing new insights into biological processes
Agilent Technologies Inc. (NYSE: A), a global leader in life
sciences, diagnostics, and applied chemical markets, and the
University of California San Diego (UC San Diego), one of the
top-ranked public research universities in the world, today
announced an innovative scientific collaboration to establish the
Agilent Center of Excellence (CoE) in Cellular Intelligence.
The Agilent CoE, located at UC San Diego’s School of Medicine,
will foster collaboration and innovation among researchers from
Agilent and UC San Diego, and other institutions and industry
partners. The CoE will serve as a hub for academic and
pharma/biopharma researchers in the region, enabling access to
vital analytical instrumentation and providing education, training,
and application development opportunities.
"This important initiative will improve our understanding of
disease mechanisms at the cellular level—and drive the development
of better methods for editing and engineering cells to treat
diseases, enhance immunity, and create novel bioproducts,” said
Mike McMullen, Agilent President and CEO.
The CoE will leverage Agilent instrumentation, including cell
analysis and mass spectroscopy solutions, to support an ambitious
transdisciplinary initiative: Decode Eukaryotic Cellular
Intelligence, a research program that aims to understand how
eukaryotic cells sense, decide, and act in complex and uncertain
environments, with implications for health and disease.
“We are thrilled to partner with Agilent to launch the Agilent
CoE in Cellular Intelligence at UC San Diego, which will advance
our understanding of the fundamental principles of life and the
origin of biological complexity,” added Dr. Pradipta Ghosh,
Professor of Medicine and Cellular and Molecular Medicine at UC San
Diego and Founding Director of the program.
The program is based on the hypothesis that eukaryotic cells
function as deep reinforcement learning (RL) agents that use
interlinked switch circuits of biological intelligence to adapt and
survive. It combines experimental, computational, and theoretical
approaches to decode the molecular and cellular mechanisms of these
switch circuits and explore their implications for health and
disease.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in
analytical and clinical laboratory technologies, delivering
insights and innovation that help our customers bring great science
to life. Agilent’s full range of solutions includes instruments,
software, services, and expertise that provide trusted answers to
our customers' most challenging questions. The company generated
revenue of $6.83 billion in fiscal 2023 and employs approximately
18,000 people worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, please
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and
Facebook.
About UC San Diego
At the University of California San Diego, a culture of
risk-taking, collaboration and innovation emerged early on.
Established in 1960, UC San Diego has been shaped by exceptional
scholars who aren’t afraid to push boundaries, challenge
expectations and redefine conventional wisdom in order to make our
world better. The only criterion our founders had for their campus
was that it must be distinctive – and being experimental has been
the norm since day one. UC San Diego is a top-ranked public
research institution and one of the most applied to universities in
the nation. Learn more at www.ucsd.edu.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240402959942/en/
Naomi Goumillout Agilent Technologies +1.978.314.1862
naomi.goumillout@agilent.com
Kellie Woodhouse UC San Diego +1.858.226.5609
kwoodhouse@ucsd.edu
Agilent Technologies (NYSE:A)
過去 株価チャート
から 5 2024 まで 6 2024
Agilent Technologies (NYSE:A)
過去 株価チャート
から 6 2023 まで 6 2024